Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease
about
Nutraceuticals in Parkinson's DiseaseSulforaphane protects against rotenone-induced neurotoxicity in vivo: Involvement of the mTOR, Nrf2, and autophagy pathways.Rotenone induction of hydrogen peroxide inhibits mTOR-mediated S6K1 and 4E-BP1/eIF4E pathways, leading to neuronal apoptosis.Host response during Yersinia pestis infection of human bronchial epithelial cells involves negative regulation of autophagy and suggests a modulation of survival-related and cellular growth pathways.Rapamycin inhibits Erk1/2-mediated neuronal apoptosis caused by cadmium.Crosstalk between Ca2+ signaling and mitochondrial H2O2 is required for rotenone inhibition of mTOR signaling pathway leading to neuronal apoptosis.1-(2-Hydroxy-5-methylphenyl)-3-phenyl-1,3-propanedione Induces G1 Cell Cycle Arrest and Autophagy in HeLa Cervical Cancer Cells.Curcumin targets the TFEB-lysosome pathway for induction of autophagy.Endogenous AMPK acts as a detrimental factor in fulminant hepatitis via potentiating JNK-dependent hepatocyte apoptosis.Mitochondrial dysfunction and Parkinson disease: a Parkin-AMPK alliance in neuroprotection.Targeting molecules to medicine with mTOR, autophagy and neurodegenerative disorders.Therapeutic potential of autophagy-enhancing agents in Parkinson's disease.mTOR Signaling in Parkinson's Disease.AMPK in Neurodegenerative Diseases.Metabolic Dysfunction in Parkinson's Disease: Bioenergetics, Redox Homeostasis and Central Carbon Metabolism.Neurotoxin mechanisms and processes relevant to Parkinson's disease: an update.Manganese and the Insulin-IGF Signaling Network in Huntington's Disease and Other Neurodegenerative Disorders.Cordyceps militaris improves the survival of Dahl salt-sensitive hypertensive rats possibly via influences of mitochondria and autophagy functions.AMP-activated protein kinase activation in mediating phenylalanine-induced neurotoxicity in experimental models of phenylketonuria.Modulating the catalytic activity of AMPK has neuroprotective effects against α-synuclein toxicity.Neuroprotective effects of vildagliptin in rat rotenone Parkinson's disease model: role of RAGE-NFκB and Nrf2-antioxidant signaling pathways.Glucose Metabolism and AMPK Signaling Regulate Dopaminergic Cell Death Induced by Gene (α-Synuclein)-Environment (Paraquat) Interactions.Targeting AMPK Signaling as a Neuroprotective Strategy in Parkinson's Disease.Punicalagin Exerts Beneficial Functions in 6-Hydroxydopamine-Treated SH-SY5Y Cells by Attenuating Mitochondrial Dysfunction and Inflammatory ResponsesmTORC Inhibitors as Broad-Spectrum Therapeutics for Age-Related Diseases
P2860
Q26752769-10199335-FDFC-4F33-9A2B-431B36DF64F1Q27314642-69A1558A-044F-4661-9877-B37FAC3D8EFFQ34760248-A2F81089-C8F4-4CD5-8C74-6924D530642BQ35082315-BA381ACF-44FF-4742-85C9-EAE02964EEB3Q36356365-0BDE0FCA-361A-4B57-B508-6D55EECEA0F5Q36946559-C41F5EDB-E5D4-4A08-A166-93094D92ECA6Q37210035-B891F9A0-A194-4423-BA47-924B880F9D01Q37689001-560AC63B-B316-4726-8749-6E910759DED1Q37745507-59A25612-9122-43F5-8580-D784C1055C95Q38539848-00988102-5BB4-4397-8DF5-13AB10BC9FFCQ38607849-78F100B9-138D-4CE1-81BA-33B2C87C1F9AQ38765856-FBE5FDDC-A876-4121-B3F3-622677A9B5CDQ38855225-6D291F62-4468-49BA-8A05-51200D052EBDQ38998405-8D56EA19-F70F-480D-9390-63A50785FEE5Q39199926-32C5869B-11E9-4FEC-94A7-EF88EC7BAC2BQ43679571-837F9A75-05E7-4A94-B613-7FF734539807Q46309597-593E60E4-4C37-48D6-97F8-30E991DAE919Q47099058-1F185172-9C17-488A-AEE3-F62E75EE99E0Q47303865-1785D652-73CF-4F78-88C5-579D3CA51A54Q47988278-B1FB7532-BB45-4390-92AA-FACB60732AE1Q48290344-0DA4A837-1545-4F9C-933F-226C712D4B93Q51691934-B77FC2E6-664B-4108-86F6-D2CAB44943DEQ52609727-601EE01C-D460-4943-B264-F9F2FC79115FQ58702868-9AB151C2-1143-490E-A75C-907BAFEBF831Q58795101-18E7508F-C7CF-4233-897D-787DF4A73847
P2860
Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease
description
2014 nî lūn-bûn
@nan
2014 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Activation of AMPK and inactiv ...... models of Parkinson's disease
@ast
Activation of AMPK and inactiv ...... models of Parkinson's disease
@en
type
label
Activation of AMPK and inactiv ...... models of Parkinson's disease
@ast
Activation of AMPK and inactiv ...... models of Parkinson's disease
@en
prefLabel
Activation of AMPK and inactiv ...... models of Parkinson's disease
@ast
Activation of AMPK and inactiv ...... models of Parkinson's disease
@en
P2093
P2860
P1433
P1476
Activation of AMPK and inactiv ...... models of Parkinson's disease
@en
P2093
Chunxiao Liu
Sujuan Chen
Yangjing Ye
P2860
P304
P356
10.1016/J.CELLSIG.2014.04.009
P50
P577
2014-04-12T00:00:00Z